Word

HITMAB

Status

Registered

Status Code

700

Status Date

Tuesday, September 27, 2022

Serial Number

79316062

Registration Number

6854569

Registration Date

Tuesday, September 27, 2022

Mark Type

4000

Filing Date

Monday, April 26, 2021

Published for Opposition

Tuesday, July 12, 2022

Trademark Owner History

Zhuhai Trinomab Pharmaceutical Co., Ltd. - Original Registrant
TRINOMAB BIOTECH CO., LTD - Owner At Publication

Classifications

5 Vaccines; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; pharmaceutical preparations for the prevention and treatment of HIV/AIDS; pharmaceutical preparations for the prevention and treatment of liver diseases; pharmaceutical preparations for the prevention and treatment of respiratory system disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases, diabetes; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; drugs for medical purposes for the prevention and treatment of HIV/AIDS; drugs for medical purposes for the prevention and treatment of liver diseases; drugs for medical purposes for the prevention and treatment of respiratory system disorders; drugs for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; drugs for medical purposes for the prevention and treatment of gastro-intestinal diseases; drugs for medical purposes for the prevention and treatment of immune system related diseases and disorders; drugs for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; biological preparations for medical purposes for the prevention and treatment of HIV/AIDS; biological preparations for medical purposes for the prevention and treatment of liver diseases; biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; biological preparations for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; medicines for human purposes for the prevention and treatment of HIV/ AIDS; medicines for human purposes for the prevention and treatment of liver diseases; medicines for human purposes for the prevention and treatment of respiratory system disorders; medicines for human purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; medicines for human purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; chemico-pharmaceutical preparations for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation; chemical preparations for pharmaceutical purposes for the treatment of viral and infectious diseases, immune system related diseases, cancer, tumors and inflammation

35 Retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies

42 Biological research; research and development of new products for others; scientific laboratory services; scientific research; chemical analysis; conducting clinical trials for others; technological research in the fields of medicine, the prevention, treatment and management of illness, health care delivery; technological research in the fields of genetics, genetic engineering, molecular biology and cellular immunology; conducting technical scientific feasibility project studies; chemistry services, namely, consultation, research and advice; chemical research

Trademark Events

Sep 22, 2023

Change Of Name/Address Rec'd From Ib

Feb 7, 2023

Final Decision Transaction Processed By Ib

Jan 18, 2023

Final Disposition Notice Sent To Ib

Jan 18, 2023

Final Disposition Processed

Dec 27, 2022

Final Disposition Notice Created, To Be Sent To Ib

Sep 27, 2022

Notice Of Registration Confirmation Emailed

Sep 27, 2022

Registered-Principal Register

Jul 18, 2022

Notification Processed By Ib

Jul 12, 2022

Official Gazette Publication Confirmation E-Mailed

Jul 12, 2022

Published For Opposition

Jun 29, 2022

Notification Of Possible Opposition Sent To Ib

Jun 29, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jun 22, 2022

Notification Of Notice Of Publication E-Mailed

Jun 6, 2022

Approved For Pub - Principal Register

Jun 6, 2022

Examiner's Amendment Entered

Jun 6, 2022

Notification Of Examiners Amendment E-Mailed

Jun 6, 2022

Examiners Amendment E-Mailed

Jun 6, 2022

Examiners Amendment -Written

Jun 3, 2022

Data Modification Completed

Jun 3, 2022

Assigned To Lie

May 25, 2022

Teas/Email Correspondence Entered

May 24, 2022

Correspondence Received In Law Office

May 24, 2022

Teas Response To Office Action Received

Feb 6, 2022

Refusal Processed By Ib

Jan 18, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Jan 18, 2022

Refusal Processed By Mpu

Dec 28, 2021

Non-Final Action (Ib Refusal) Prepared For Review

Dec 27, 2021

Non-Final Action Written

Dec 22, 2021

Assigned To Examiner

Jul 27, 2021

Application Filing Receipt Mailed

Jul 23, 2021

New Application Office Supplied Data Entered

Jul 22, 2021

Sn Assigned For Sect 66a Appl From Ib